Business
Sernova Announces Peer Reviewed Publication Demonstrating Safety and Efficacy of a Novel Cell Pouch Cell Therapy Approach for Treatment of Severe Hemophilia A
(TheNewswire) LONDON, ONTARIO – TheNewswire - January 20, 2022...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova Announces Peer Reviewed Publication Demonstrating Safety and Efficacy of a Novel Cell Pouch Cell Therapy Approach for Treatment of Severe Hemophilia A\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n LONDON, ONTARIO –\n \n \n TheNewswire -\n \n \n January 20, 2022 – Sernova Corp. (TSXV:SVA)\n(OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage regenerative medicine\nand cell therapy therapeutics company developing a potential\n‘functional cure’ for chronic diseases is pleased to announce a\npeer reviewed published scientific journal article highlighting\nsuccessful development of a novel cell therapy approach for treatment\nof severe hemophilia A , a serious genetic bleeding disorder caused by\nmissing factor VIII (FVIII) activity in the blood stream.\n \n \n \n \n The journal article entitled “Efficient and Safe\nCorrection of Hemophilia A by Lentiviral Vector-Transduced BOECs in an\nImplantable device (Sernova’s Cell Pouch\n \n \n ™\n \n \n ),” was published in the\nprestigious scientific journal, Molecular Therapy: Methods &\nClinical Development, Volume 23, December 2021.\n \n \n \n \n The therapeutic approach includes use of the\npatient’s own cells obtained from a blood sample, which are then\nmodified using a lentiviral vector-mediated gene transfer procedure\nusing the B-domain deleted form of FVIII under the control of an\nendothelial-specific promoter and subsequently transplanted within\nSernova’s vascularized Cell Pouch into a mouse model of hemophilia\nA. These cells then provide a continuous therapeutic release of factor\nVIII into the bloodstream. The publication highlights that the\nHemAcure Consortium has now successfully demonstrated safety and\nlong-term improvement in blood clotting in a hemophilia A mouse model.\n \n \n \n \n It is estimated that 115,000 people live with\nhemophilia A in North America and Europe with a significant proportion\nwho rely on regular infusions of FVIII. Treatment costs per patient\nare as high as US $200,000 each year, with an aggregate therapeutic\ncost of over US$ 10 billion per year.\n \n \n \n \n “This novel ex vivo gene therapy approach is the\nfirst demonstration showing the safety and feasibility of\ntransplantation of lentiviral-corrected blood outgrowth endothelial\ncells (BOECs) within an i...